Objectives: To quantify the performance of existing first-line and second-line combination antiretroviral therapy (cART) regimens on patient's clinical outcomes in the Netherlands using ATHENA data and to evaluate the potential for new drug regimens to improve patient's clinical outcomes using a data-based mathematical model.
Introduction
Since the introduction of combination antiretroviral therapy (cART) in 1996, HIV treatment has improved substantially [1] [2] [3] . The improved efficacy of cART in supressing HIV replication has reduced mortality of HIV-patients on treatment [4] [5] [6] , and transformed HIV into a long-term chronic infection for many patients [2, 7] , with mortality rates among HIV-infected patients on cART approaching those of the general population [6] .
There is a growing range of antiretroviral drugs that are used to provide life-long therapy. Although the most limiting factors of HIV treatment have shifted over time [2] , there are still a number of problems associated with cART that challenge the regimens durability, such as considerable cross-resistance within drug-classes [8] , and potential, sometime serious, adverse effects, which can make adherence to regimens difficult [9] [10] [11] .
Prolonging the durability of first-line cART is particularly important for the management of HIV infection. Patients on subsequent lines often receive more complex and expensive regimens [4] [5] [6] , and switching is associated with 'transactional' costs, including clinical visits, and laboratory tests. Moreover, patients, who achieve undetectable levels of viral load on first-line have a greater chance of long-term success on HIV-treatment [12] .
The aim of this study is to quantify the performance of existing first-line and second-line cART regimens on patient's clinical outcomes in the Netherlands using ATHENA data and to investigate the potential of new drug regimens using a data-based mathematical model.
Methods

Data
ATHENA is a national observational cohort that includes all HIV-patients followed in the 25 designated HIV treatment centres in the Netherlands since 1998. The design of this cohort has been described in detail previously [13] . Clinical, biological and immunological data on HIV-infected patients are collected upon entry and at each follow-up visit. Reasons for stopping a current regimen are determined by physicians at the date of regimen change from a list of reasons provided by the ATHENA cohort. This analysis included all Dutch-born male patients, who were treatment-naive when beginning cART and who began cART between 1 January 2000 and June 2010 (n ¼ 3995). cART was defined as regimens containing three or more antiretroviral drugs. Women were not included in this analysis because of the treatment changes that occur during pregnancy.
We defined a switch as a change in regimen that included at least one new antiretroviral drug. Reasons for switching were classified as first, toxicity; second, simplification/ new medication becoming available; third, virological failure, and fourth, other reasons. 'Toxicity' is defined as the need to change regimen due to side effects. 'Simplification/new medication becomes available' refers to the situation in which patients switch regimen for a simpler cART regimen, for example a once-daily regimen, or because a new, better cART regimen has become available. 'Virological failure' refers to a switch due to poor virological response, including resistance. 'Other reasons' included 'pharmacological', 'caution', 'other' and 'unknown' reasons as classified by the ATHENA cohort. 'Pharmacologic reason' refers to an interaction with co-medication and 'caution' to the situation in which a patient is starting an additional treatment, for example chemotherapy, and the regimen is changed as the combination of side effects may be too heavy. Apart from the four categories of reasons, (a) to (d) defined above, there were other drug-related reasons for switching treatment (compliance, co-infection, hospital admittance, and contra-indication), which were excluded as they accounted for less than 1% of switches. The same baseline epidemiological, healthcare and demographic inputs, based on ATHENA data, are used throughout the analysis, except where otherwise specified ( Table 1) . HIV-related mortality was modelled as independent of time on cART, as the estimated hazard of dying was not significantly dependent on time on cART in the ATHENA data.
The model allows tracking of patient's outcomes, including calculating survival time and average time on first-line and second-line cART. The model simulates changes in patient's outcomes when prescribed a new drug regimen, with either improved toxicity or virological failure profiles, two potential targets for future drug development.
Results
Data
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considerably over the course of the last decade. The decline is particularly evident in first-line cART (Fig. 1a Analysis of the Dutch ATHENA data found that among Dutch-born men, diagnosed with HIV from 1996 onward, the main reason for switching current first-line and second-line regimens was toxicity, accounting for around 50% of switching first-line and second-line cART (Fig. 1 ). Despite the decline in the incidence of switching from first-line cART between 2000-2005 and 2005-2010, toxicity is still the dominant reason for switching cART regimens.
Model
We simulated the impact of a new drug regimen, with improved profile on patient's outcomes using a mathematical model. Model simulations found that a new drug regimen would have the highest impact if it had an improved toxicity profile (Fig. 1c) . A new drug regimen with a 50% reduction (from 90 to 45 events per 1000 person-years) in incidence of toxicity compared with current cART would result in three additional lifemonths per patient (Fig. 1c) to an average survival time of 32 years after start of treatment. In comparison, a 50% reduction in virological failure would add less than 1 month to patient's survival time after treatment initiation (Fig. 1c ).
The results further showed that a new drug regimen would have the highest impact if used as first-line cART. Used as first-line, a new drug regimen with a 50% reduction (from 90 to 45 events per 1000 person-years) in incidence of toxicity can potentially add 5 months to patient's survival time compared with no change in survival time if used as second-line.
A new first-line drug regimen would also simplify patient management, as fewer patients experience problems with their regimen and therefore remain on first-line cART for longer. A new drug regimen with a 50% reduction in incidence of toxicity compared with current treatment regimens could reduce the number of patients, who have to switch first-line cART by 16% and increase the average duration on first-line cART by nine months per patient.
Discussion
Among HIV-infected men in the Netherlands, the main reason for switching regimens is toxicity, and model simulations found that use of a new drug regimen with a reduction in these toxicity rates could translate into a potential increase in survival time and time on first-line cART, to the benefit of patient management. The model highlighted the importance of using new improved drug regimens as first-line cART in order to maximise clinical outcomes and simplify patient management. The relatively low impact a new drug regimen can have on survival is due to the high performance of existing regimens as evident by the improvement in performance shown by the analysis of ATHENA data and marked increase in life-expectancy of HIV-infected individuals in European countries, including the Netherlands since 1996 [1, 15, 16] . Moreover, patients, who experience toxicity could switch regimen without experiencing virological failure, thus having little impact on survival. However, although newer, bettertolerated regimens may have a limited impact on patients' survival, they will simplify patient management and improve patient's quality of life.
Our findings are consistent with other studies. Research conducted into the reasons for switching treatment suggests that toxicity is the main reason patients switch their regimens [17] [18] [19] [20] . Model results are consistent with studies documenting that effective treatment has increased patients' life expectancy [1, 16, 21, 22] . There may be a number of mechanisms driving the increased mortality rate in patients switching first-line due to toxicity. Patients could have difficulty adhering to the regimen because of the side effects and consequently do less well virologically and/or clinically. These could be patients who are more likely to experience side effects, for example due to their reduced body mass, so that higher concentrations of the medication are in the body [19, 23] .
To our knowledge, this analysis of ATHENA data is the first attempt to look at the factors that drive switching cART and the potential impact of new drug regimens in the Netherlands. Coupled with the model, it provides a valuable insight into the potential of new drug regimens and the impact these can have on patients' outcomes and patient management in the Netherlands in the future.
The results suggest that the data requires further analysis to identify the side effects that result in switching, as well as their effect on patients' long-term outcome. Interpretation of the model output would be wrong if switching and reduced survival on second-line is entirely due to switching being a marker for low adherence. The model analysis is limited by its reliance on assumptions and on data from the literature, in which ATHENA data was not available or sufficient, especially for biological assumptions regarding disease progression. The model uses longterm extrapolations from the patient data and assumes that switching rates are independent of CD4 cell count. The mathematical model did not include certain complexities, for example the inclusion of failure rates for different treatment regimens, as it has been well documented that earlier regimens, such as stavudine and some zidovudinebased regimens are associated with high toxicity rates [24] [25] [26] or including time-dependent variation of switching rates, as the incidence of these have been shown to vary during the first and subsequent years on cART [27, 28] . Incorporation of individual-based adherence into the model, which has been shown to be associated with the development of resistance [27, [29] [30] [31] , could assist in investigating the reason for poor response to second-line treatment [32] . However, we believe that this model provides a suitable framework with which to describe potentials of new drug regimens in the future.
In conclusion, new drug regimens with improved toxicity profiles will have the greatest impact on patient prognosis and patient management in the Netherlands.
M.S. formulated the research question, constructed the model, interpreted results and wrote the first draft of the article. C.S. carried out the data analysis of the ATHENA cohort for the data and model part of the work. I.C. assisted in the model construction. G.P.G., T.H. and F.W. contributed to the formulation of the research question, and the interpretation of the data and model output. All authors contributed to the re-drafting of the article and in the process of approving the final draft.
